Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis

Purpose We aimed to systematically evaluate the efficacy and safety of adalimumab biosimilar agents in the treatment of moderate-to-severe plaque psoriasis, in order to provide evidence-based reference data for clinical medicine. Materials and Methods Five databases were searched by electronic retri...

Full description

Bibliographic Details
Published in:	Journal of Dermatological Treatment
Main Authors:	Changkun Li, Yixuan Sunhe, Hui Zhou, Weihua Dong
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Subjects:	adalimumab biosimilar psoriasis efficiency safety meta-analysis
Online Access:	http://dx.doi.org/10.1080/09546634.2023.2249145

Similar Items

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
by: Marco May Lee, et al.
Published: (2025-07-01)

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab
by: Angela Fico, et al.
Published: (2025-05-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
by: Martina Maurelli, et al.
Published: (2023-12-01)

Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
by: Yasameen Abbas, et al.
Published: (2024-12-01)

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
by: David M. Pariser, et al.
Published: (2025-03-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
by: Vandana Midha, et al.
Published: (2018-01-01)

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
by: Ran Jin, et al.
Published: (2025-03-01)

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
by: Alan Menter
Published: (2023-10-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023-04-01)

Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials
by: Vibeke Strand
Published: (2025-06-01)

Unilateral Verrucous Psoriasis Successfully Treated With Adalimumab
by: Artur Antônio Duarte, et al.
Published: (2024-01-01)

Navigating adalimumab biosimilars: an expert opinion
by: Vered Abitbol, et al.
Published: (2023-10-01)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
by: Hong Zhang, et al.
Published: (2021-04-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study
by: Fanny Alcira Reyes Neira, et al.
Published: (2025-02-01)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
by: Claudiu Costinel Popescu, et al.
Published: (2022-12-01)

Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study
by: Yachen Wang, et al.
Published: (2025-07-01)

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study
by: W. H. A. van Poecke, et al.
Published: (2025-07-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

Diffuse large B-cell lymphoma that develops after adalimumab using adalimumab in a patient with psoriasis
by: Esra Yıldırım Bay, et al.
Published: (2021-06-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study
by: Fanny Reyes-Neira, et al.
Published: (2025-10-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

Eosinophilia Induced by Biosimilar Adalimumab (CinnoRA) in a Patient with Psoriasis and Psoriatic Arthritis: A Case Report
by: Saedpanah R, et al.
Published: (2025-09-01)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
by: Fang Wang, et al.
Published: (2023-10-01)

Meta-analysis of efficacy and safety of adalimumab injection for arthropathic psoriasis
by: Nan LI, et al.
Published: (2019-02-01)

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
by: Ahmadreza Jamshidi, et al.
Published: (2017-07-01)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
by: Savas Yayli, et al.
Published: (2013-11-01)

Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study
by: Ancona S, et al.
Published: (2025-04-01)

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis
by: Dandan HU, et al.
Published: (2023-06-01)

Safety profiles of biosimilars vs. their EU reference products: INNs (adalimumab, bevacizumab, trastuzumab, rituximab, infliximab, etanercept)
by: Valentin Kopanarov, et al.
Published: (2025-07-01)

Adalimumab induced psoriasis in a Crohn’s disease patient: a case report
by: Dhaifallah Alrakawi Alenizi
Published: (2024-06-01)

A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
by: Rodrigo Garcia-Salinas, et al.
Published: (2025-05-01)

Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis
by: Ying Wang, et al.
Published: (2024-04-01)

The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis
by: Aleksandra Lesiak, et al.
Published: (2025-06-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
by: Alexandra Azevedo, et al.
Published: (2018-09-01)

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers
by: Eva Dokoupilová, et al.
Published: (2024-06-01)

Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
by: Ran Jin, et al.
Published: (2024-03-01)